Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension

Actelion Pharmaceuticals Ltd / Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension . Verarbeitet und übermittelt durch Nasdaq OMX Corporate Solutions. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. Source: Globenewswire

Dear member of the investment community

Actelion announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH).

An investor conference call & webcast will be held to discuss the approval at 14:00hrs on 05 January 2016.

Date/Time:

  
  
Conference Call and Webcast
Participants will find dial-in information and a link to the webcast on the Actelion website www.actelion.com at least 24hrs ahead of when the conference is due to start.

Webcast Replay:
The archived Investor Webcast will be available for replay through www.actelion.com approximately 60 minutes after the call has ended.

--- Ende der Mitteilung ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Schweiz

ISIN: CH0010532478;